Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery

  • End date
    Dec 31, 2028
  • participants needed
  • sponsor
    West China Hospital
Updated on 2 March 2022


It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine, lomustine and vincristine) could improve progression-free survival (PFS) and overall survival (OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide to treat these patients, though large-scale prospective studies are lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and OS in patients with high-risk low-grade gliomas.

Condition Low-grade Glioma
Treatment Temozolomide, Intensity Modulated Radiation Therapy
Clinical Study IdentifierNCT04316039
SponsorWest China Hospital
Last Modified on2 March 2022


Yes No Not Sure

Inclusion Criteria

Newly diagnosed supratentorial WHO grade II gliomas
Aged 18 to 39 years without total resection, or aged 40 to 70 years with any extent of resection or biopsy
Karnofsky performance score (KPS) 60
No more than moderate neurologic symptoms and signs
The interval between surgery and randomization is less than 12 weeks
Have signed the consent form. -

Exclusion Criteria

WHO grade I gliomas or high-grade gliomas according to WHO's grading system
Have received prior radiation therapy to the head and neck region
Have received prior chemotherapy
Synchronous multiple primary malignant tumor excluding carcinoma of the cervix in situ or nonmelanomatous skin cancer
Prior malignancy's disease-free survival less than 5 years
Have active infection
Patients are pregnant or breast-feeding. -
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note